Approximately 12% of American adults — roughly 1 in 8 — have taken a GLP-1 medication. That's a staggering adoption rate for a drug class that barely registered in public awareness before 2022. But here's the number that should stop you: only 13 states cover GLP-1s for obesity through Medicaid. That's down from 16 states in 2025.
The access gap isn't narrowing. It's widening. And it's widening for the population that needs these medications most.
The Scale of GLP-1 Adoption
To grasp how fast GLP-1s have moved from niche diabetes treatment to mainstream health intervention, consider the trajectory. In 2024, Medicare alone processed 21.8 million GLP-1 claims totaling $27.5 billion in gross spending. Medicaid added another 8.4 million prescriptions and $8.6 billion. Combined with commercial insurance and cash-pay prescriptions, the U.S. GLP-1 market hit approximately $52.8 billion in 2025 and is projected to reach $58 billion in 2026.
The global market for GLP-1 medications used specifically for obesity — not diabetes — is growing at 23.4% annually and projected to reach $40.3 billion in North America alone by 2035.
These aren't niche medications anymore. They're one of the most prescribed drug classes in America. But the distribution of access looks nothing like the distribution of need.
The Medicaid Retreat
Medicaid, which covers approximately 90 million Americans — disproportionately lower-income, disproportionately affected by obesity — has been moving in the wrong direction. As of January 2026, only 13 states provide Medicaid coverage for GLP-1 obesity treatment, down from 16 in 2025.
The reasons are financial. A single patient on branded Wegovy costs a Medicaid program roughly $16,000 per year at list price. Multiply that by the eligible population in any given state and the budget math becomes politically impossible, especially as federal funding cuts and state budget challenges intensify.
The CMS BALANCE Model aims to address this by allowing state Medicaid agencies to join a federal program providing GLP-1 coverage, beginning as early as May 2026 through January 2027. But state participation is voluntary, manufacturer participation is required, and the operational details are still being finalized.
The Insurance Coverage Map
Understanding where you fall in the coverage landscape determines your realistic options:
Medicare Part D: Starting July 1, 2026, the GLP-1 Bridge program provides coverage at $50/month for Wegovy, oral Wegovy, and Zepbound for beneficiaries with BMI ≥35 (or ≥30 with comorbidities). This is temporary through December 2027.
Commercial insurance: Most major commercial insurers cover GLP-1s for type 2 diabetes. Coverage for obesity is expanding but not universal, and often requires prior authorization, step therapy (trying other treatments first), and BMI documentation. Employer plans vary widely.
Medicaid: Coverage depends entirely on your state. Of the 13 states currently providing coverage, restrictions vary from strict prior authorization to limited formulary options. Compounded GLP-1s are not covered by any state Medicaid program.
No insurance / excluded: Cash-pay options through telehealth platforms range from roughly $99/month (compounded, where still available) to $299+/month (branded). Manufacturer savings cards from Novo Nordisk and Eli Lilly can reduce costs for eligible patients.
Where Telehealth Fills the Gap
For the millions of Americans in coverage gaps — too young for Medicare, in states without Medicaid coverage, or with commercial plans that exclude obesity treatment — telehealth has become the primary access pathway. The pricing competition among telehealth platforms has driven cash-pay costs down substantially over the past year.
What You Can Do
If you're currently uninsured or underinsured for GLP-1 obesity treatment:
- Check your state's Medicaid status: If your state is among the 13 with coverage, apply. If not, check whether your state is joining the BALANCE Model in 2026.
- Review commercial plan formularies: Open enrollment is an opportunity to switch to a plan that covers anti-obesity medications. Ask specifically about Wegovy and Zepbound coverage before selecting a plan.
- Explore manufacturer assistance: NovoCare (Novo Nordisk) and LillyDirect (Eli Lilly) offer savings programs and patient assistance for eligible patients.
- Compare telehealth cash-pay pricing: Platforms vary significantly in what's included — medication only vs. medication plus labs, coaching, and follow-up. The cheapest monthly price isn't always the best value.